Thalidomide Plus Radiation Shows Promise in the Treatment of Certain Brain Tumors

Publication
Article
OncologyONCOLOGY Vol 15 No 10
Volume 15
Issue 10

According to a study conducted by the Radiation Therapy Oncology Group, thalidomide (Thalomid) in combination with radiation therapy shows promise in treating malignant brain tumors. Study findings were presented at the annual meeting of

According to a study conducted by theRadiation Therapy Oncology Group, thalidomide (Thalomid) in combination withradiation therapy shows promise in treating malignant brain tumors. Studyfindings were presented at the annual meeting of the American Society ofClinical Oncology (ASCO).

Thalidomide is known to have antiangiogenic properties, saidlead author Alfred Yung, MD, acting chairman of the department of neuro-oncologyat M. D. Anderson Cancer Center. In the study, 89 patients with glioblastomaswere given thalidomide in combination with radiation therapy and compared toseveral hundred patients treated with standard chemotherapy (carmustine [BiCNU])and radiation.

The survival difference between the two groups was notsignificant, and there were no major side effects with thalidomide. The mostnotable side effects were numbness in the hands and feet and fatigue (which isusually manageable).

"We think there is good potential for use of this drug, perhaps incombination with other antiangiogenic or cytotoxic agents, in the future,"said Dr. Yung. "These malignant brain tumors are very vascular and verydependent on a good blood supply. Clearly, thalidomide can help cut off thissupply."

Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Related Content